Viridian Continues Building Case For Veligrotug In TED
Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.
Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.